GLYCOSENSORS AND DIAGNOSTICS, LLC — Department of Health and Human Services STTR Phase I: 300

GLYCOSENSORS AND DIAGNOSTICS, LLC — STTR Phase I award from Department of Health and Human Services.

Amount
$698,157
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
STTR · Phase I
Topic
300
Solicitation
PA11-214
NAICS
Place of performance
GA
Period
2015-01-15 → 2017-06-30

Description

DESCRIPTION provided by applicant Glycans have several distinct properties that make their development as disease biomarkers appealing Firstly their location on cell surfaces makes them the first point of contact for cellular interactions and thus they are crucial in the control of normal metabolic processes and conversely they function as pathogen adhesion receptors Secondly specific glycan structures that are not present or are in low amounts in normal state proliferate or alter their sequence in disease states And lastly changes in glycosylation may be found in many proteins including those that are highly abundant Thus changes in the normal levels of glycan structures such as terminal sialic acid may be markers of disease states New highly specific reagents are required in order to overcome current limitations in the discovery and exploitation of disease related glycans Using structurally guided genetic manipulations we will convert the NanB sialidase from S pneumococcus into a high specificity affinity reagent for the detection of sialic acid modifications of glycopeptides and glycoproteins Because such a protein has lectin like properties but is derived from an enzyme it is called a andquot Lectenz r andquot A NanB Lectenz r addresses a key need in disease glycomarker detection namely a robust and easy to produce reagent specific for linked sialic acid This reagent could be employed in an affinity matrix for sample enrichment which in conjunction with existing MS based methods could provide linkage information It could also be employed in histological studies or Western blots etc Lectenz r offer numerous advantages over plant lectins they are engineered to be high affinity and yet retain the exquisite substrate specificityof the endogenous enzyme they may be efficiently produced and for human homologues have the potential to be employed in vivo with low toxicity Whereas some aspects of Lectenz r development parallel those of antibody evolution Lectenz r have the tremendous benefit of employing a protein naive template that has the desired specificity PUBLIC HEALTH RELEVANCE Using structurally guided genetic manipulations we will convert the NanB carbohydrate processing enzyme into a high specificity affinity reagent called a Lectenz r for the detection of disease related sialic acid modifications of glycopeptides and glycoproteins The principle advantages of engineered Lectenz r over other reagents such as antibodies or lectins is that they have exquisite substrate specificity that is not context dependent they may be evolved to have desirable binding kinetics and that they may be efficiently produced as monomeric proteins